4 results about "Cyclosporin a" patented technology

The present application belongs to the field of cell biology, specifically by adding recombinant human DFF45 protein, Z-VAD-FMK, Cyclosporin A, bFGF, N-Acetylcysteine, regulating the activity and effect of apoptosis-specific nuclease, reducing the apoptosis rate of umbilical cord mesenchymal stem cells, and also can improve the proliferation effect of umbilical cord mesenchymal stem cells, the proliferation rate of umbilical cord mesenchymal stem cells is increased by 17.53%, and the apoptosis rate of umbilical cord mesenchymal stem cells by ordinary conventional culture method is reduced from 14.32% to 9.81%, effectively solving the core problem of stem cell proliferation attenuation, apoptosis rate increase in the existing culture technology, maintaining the biological activity and quality stability of stem cells in the long-term subculture process, providing reliable technical support and experimental basis for the large-scale culture, in vitro expansion and subsequent clinical transformation application of umbilical cord mesenchymal stem cells.

The present application relates to a cyclosporine A detection reagent and its preparation and detection method, specifically relates to a cyclosporine A chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti-cyclosporine A specific antibody, indicating reagent for detecting anti-cyclosporine A specific antibody-cyclosporine A combination;The above-mentioned anti-cyclosporine A specific antibody is obtained by immunizing animals with cyclosporine A immunogen.The present application has the advantages that: the cyclosporine A immunogen of the present application is specific and has high immunogenicity, and the prepared anti-cyclosporine A specific antibody is specific and has high titer;The chemiluminescence immunoassay reagent containing the above-mentioned anti-cyclosporine A specific antibody can conveniently, quickly and accurately determine the content of cyclosporine A in the sample, and multiple samples can be simultaneously determined on a fully automatic chemiluminescence immunoassay analyzer, realizing high-throughput rapid determination of cyclosporine A, high accuracy, strong specificity, and great improvement in accuracy and detection efficiency.

The invention provides a nano antibody for detecting cyclosporine A and application of the nano antibody, and belongs to the technical field of medical detection. The nano antibody comprises complementarity determining regions CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is as shown in SEQ ID NO: 1; the amino acid sequence of the CDR2 is as shown in SEQ ID NO: 2; the amino acid sequence of the CDR3 is as shown in SEQ ID NO: 3. When the nano antibody is used for detecting cyclosporin A, the precision is high, the sensitivity is high, the specificity is good, and the detection result is accurate and reliable.

A lipid nano drug delivery system targeting a brain lesion and a preparation method and application thereof. The drug delivery system comprises a lipid, a delivery drug, and a functional penetrating peptide, and the functional penetrating peptide is formed by covalently connecting a peptide chain linking a nanocarrier end, an arginine-rich penetrating peptide, a matrix metalloproteinase-9 sensitive peptide, and a polyanion inhibitory peptide. The lipid nano drug delivery system can be used for targeting the brain lesion and realizing mitochondrial enrichment by means of modification of the functional penetrating peptide. The repair of mitochondria is realized by encapsulating peptide drug cyclosporin A by means of a lipid nanoparticle core by utilizing a dilution-induced precipitation technique, thereby solving the problems that current cyclosporin A is difficult to effectively reach a brain lesion and the therapeutic window is small, and improving the ability to repair cells around the brain lesion with a small administration dose.